A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Prostate cancer, a prevalent male cancer, can be detected early through a simple PSA blood test, significantly reducing ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Contrary to recommendations regarding age and PSA screening, over the course of nearly two decades the highest PSA testing ...

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

PSA testing remains controversial because it can lead to healthy men being diagnosed and treated unnecessarily ...